SG11202101814RA - Compositions of cxcr4 inhibitors and methods of preparation and use - Google Patents

Compositions of cxcr4 inhibitors and methods of preparation and use

Info

Publication number
SG11202101814RA
SG11202101814RA SG11202101814RA SG11202101814RA SG11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA
Authority
SG
Singapore
Prior art keywords
compositions
preparation
methods
cxcr4 inhibitors
cxcr4
Prior art date
Application number
SG11202101814RA
Inventor
Karel Marie Joseph Brands
Original Assignee
X4 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Inc filed Critical X4 Pharmaceuticals Inc
Publication of SG11202101814RA publication Critical patent/SG11202101814RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202101814RA 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use SG11202101814RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726010P 2018-08-31 2018-08-31
US16/215,963 US10548889B1 (en) 2018-08-31 2018-12-11 Compositions of CXCR4 inhibitors and methods of preparation and use
PCT/US2019/049065 WO2020047410A1 (en) 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use

Publications (1)

Publication Number Publication Date
SG11202101814RA true SG11202101814RA (en) 2021-03-30

Family

ID=69230180

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101814RA SG11202101814RA (en) 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use

Country Status (13)

Country Link
US (4) US10548889B1 (en)
EP (1) EP3843720A4 (en)
JP (1) JP2021535146A (en)
KR (1) KR20210095118A (en)
CN (1) CN112839649A (en)
AU (1) AU2019328530A1 (en)
BR (1) BR112021003467A2 (en)
CA (1) CA3110735A1 (en)
EA (1) EA202190377A9 (en)
IL (1) IL281082A (en)
MX (1) MX2021002180A (en)
SG (1) SG11202101814RA (en)
WO (1) WO2020047410A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069486A (en) 2015-12-14 2018-12-21 X4 制药有限公司 The method for the treatment of cancer
ES2907489T3 (en) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Cancer treatment methods
CN108883091A (en) 2015-12-22 2018-11-23 X4 制药有限公司 Method for treating immunologic deficiency disease
JP2019510785A (en) 2016-04-08 2019-04-18 エックス4 ファーマシューティカルズ, インコーポレイテッド How to treat cancer
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11878009B2 (en) * 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
CA3171250A1 (en) * 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
KR20240089380A (en) * 2021-10-07 2024-06-20 엑스4 파마슈티컬스 인코포레이티드 Synthesis of Maborixapo and its intermediates
WO2023107689A1 (en) * 2021-12-09 2023-06-15 X4 Pharmaceuticals, Inc. Methods for treating primary immunodeficiency
WO2023240259A1 (en) * 2022-06-10 2023-12-14 X4 Pharmaceuticals, Inc. Treatments for conditions involving increased il-6 levels

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
AU6887996A (en) 1995-09-01 1997-04-01 Washington University School Of Medicine Method of reducing neurotoxic injury with zinc chelators
EE9800299A (en) 1996-03-22 1999-06-15 The Du Pont Merck Pharmaceutical Company Novel asymmetric synthesis of R-α-propyl-piperonylamine and its analogs
DE69807222T2 (en) 1997-06-02 2003-04-17 Janssen Pharmaceutica Nv (IMIDAZOL-5-YL) METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF PROLIFERATION OF SMOOTH MUSCLE CELLS
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
ID23991A (en) 1997-09-30 2000-06-14 Daiichi Seiyaku Co SULFONIL DRIVINGS
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
EP1039899A2 (en) 1997-12-19 2000-10-04 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
US6607799B1 (en) 1998-10-15 2003-08-19 3M Innovative Properties Company Surgical dressing with delivery system and method of manufacture
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
PL350998A1 (en) 1999-03-24 2003-02-24 Anormed Inc Chemokine recpetor binding heterocyclic compounds
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
MXPA03002325A (en) 2000-09-15 2003-06-24 Anormed Inc Chemokine receptor binding heterocyclic compounds.
WO2002022600A2 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
HUP0302960A3 (en) 2000-09-15 2007-03-28 Anormed Inc Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
EA007538B1 (en) 2000-12-11 2006-10-27 Туларик Инк. Cxcr3 antagonists
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
WO2002088112A1 (en) 2001-04-27 2002-11-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
LT2371361T (en) 2001-07-31 2019-09-10 Genzyme Corporation Methods to mobilize progenitor/stem cells
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030055876A1 (en) * 2001-08-29 2003-03-20 Aravinda Korala Printing web content from self-service kiosks
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
CN101353324A (en) 2001-09-12 2009-01-28 阿诺麦德股份有限公司 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
WO2003055876A1 (en) 2001-12-21 2003-07-10 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7491544B2 (en) 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
IL166718A0 (en) 2002-08-14 2006-01-15 Atugen Ag Further use of protein kinase n beta
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co Nitrogen-containing heterocyclic compounds and medicinal use thereof
CN1826331A (en) 2003-04-03 2006-08-30 塞马福尔药业公司 Pi-3 kinase inhibitor prodrugs
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
WO2004093817A2 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
ZA200509718B (en) 2003-05-30 2007-03-28 Gemin X Biotechnologies Inc Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
EP2371835A1 (en) 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
AU2005224079A1 (en) * 2004-03-15 2005-09-29 Anormed, Inc. Process for the synthesis of a CXCR4 antagonist
CA2561718A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004021716A1 (en) 2004-04-30 2005-12-01 Grünenthal GmbH Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds
ES2605792T3 (en) 2004-05-13 2017-03-16 Icos Corporation Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
WO2006020415A1 (en) 2004-08-02 2006-02-23 Smithkline Beecham Corporation Chemical compounds
EP1789045A2 (en) 2004-08-16 2007-05-30 Smithkline Beecham Corporation Chemical compounds
JP2008511669A (en) 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション Compound
JP2008514622A (en) 2004-09-24 2008-05-08 スミスクライン ビーチャム コーポレーション Compound
TW200619206A (en) 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
ES2337496T3 (en) 2005-01-19 2010-04-26 Rigel Pharmaceuticals, Inc. PROFESSIONALS OF 2,4-PYRIMIDINDIAMINE COMPOUNDS AND THEIR USES.
JP2008531716A (en) 2005-03-04 2008-08-14 スミスクライン ビーチャム コーポレーション Compound
KR101533268B1 (en) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007006408A2 (en) 2005-07-08 2007-01-18 Bayer Healthcare Ag Methods and kits for predicting and monitoring direct response to cancer therapy
EP1904501A2 (en) 2005-07-11 2008-04-02 Smithkline Beecham Corporation Chemical compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0614256B1 (en) 2005-08-02 2018-10-16 Ineos Europe Ltd process for producing conjugated diene homopolymers or copolymers
US20070043012A1 (en) 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
BRPI0617162B8 (en) 2005-10-07 2021-05-25 Exelixis Inc phosphatidylinositol 3-kinase inhibitor compounds pharmaceutical compositions containing them and methods of using them
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
ES2407115T3 (en) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compound containing a basic group and its use
CA2629037A1 (en) 2005-11-30 2007-06-07 Schering Corporation Compositions comprising a combination of ccr5 and cxcr4 antagonists
CN103214483B (en) 2005-12-13 2014-12-17 因塞特公司 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
EP1984375A2 (en) 2006-01-25 2008-10-29 Smithkline Beecham Corporation Chemical compounds
TW200738711A (en) 2006-01-25 2007-10-16 Smithkline Beecham Corp Chemical compounds
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
AU2007246793B2 (en) 2006-04-26 2013-02-07 F. Hoffmann-La Roche Ag Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor
CN101431895A (en) 2006-05-01 2009-05-13 卡普里康制药公司 Novel triptan formulations and methods for making them
US20090247570A1 (en) 2006-06-12 2009-10-01 Pfizer Inc Pharmaceuticals
TWI482772B (en) 2006-08-21 2015-05-01 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo(4,5-d)pyrimidin derivate
CN102887900B (en) 2006-09-22 2015-04-29 药品循环公司 Inhibitors of bruton's tyrosine kinase
CN104030990B (en) 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 Phenyl amino pyrimidine compounds and application thereof
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PT2155747E (en) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2009026251A1 (en) 2007-08-17 2009-02-26 The General Hospital Corporation Detecting ions and measuring ion concentrations
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
DK2288610T3 (en) 2008-03-11 2016-11-28 Incyte Holdings Corp Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
EP2252318A4 (en) 2008-03-20 2012-04-18 Carolus Therapeutics Inc Methods of treating inflammation
DK2262808T3 (en) 2008-03-28 2013-11-04 Altiris Therapeutics CHEMOKINE RECEPTOR MODULATORS
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010016628A (en) 2008-07-03 2010-01-21 Canon Inc Image processing device and image processing method
TWI432436B (en) 2008-12-09 2014-04-01 Gilead Sciences Inc Modulators of toll-like receptors
US9119790B2 (en) 2009-09-28 2015-09-01 Zenbury International Limited Pharmaceutical composition
US20110293521A1 (en) 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
CA2706292A1 (en) 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US9155723B2 (en) 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
WO2012075362A2 (en) 2010-12-03 2012-06-07 Emory University Chemokine cxcr4 receptor modulators and used related thereto
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Methods of inhibiting metastasis from cancer
BR122021026169B1 (en) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania USE OF A CELL
US9314450B2 (en) 2011-01-11 2016-04-19 Dimerix Bioscience Pty Ltd. Combination therapy
KR20210094672A (en) 2011-05-16 2021-07-29 젠자임 코포레이션 Use of cxcr4 antagonists
AR087364A1 (en) 2011-07-29 2014-03-19 Pf Medicament ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20150004239A1 (en) 2012-01-12 2015-01-01 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
US20150301058A1 (en) 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
CA2914487A1 (en) 2013-06-05 2014-12-11 Salk Institute For Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
WO2015019284A2 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
PL3650014T3 (en) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
CN105828834A (en) 2013-11-05 2016-08-03 同源生物服务股份有限公司 Combinations of checkpoint inhibitors and therapeutics to treat cancer
US10280183B2 (en) 2014-03-18 2019-05-07 The Research Foundation For The State University Of New York Therapeutic agent for treating tumors
DK3119397T3 (en) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders
WO2015200341A1 (en) 2014-06-23 2015-12-30 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
US20170340693A1 (en) 2014-12-12 2017-11-30 Commonwealth Scientific And Industrial Research Organisation Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
BR112017026189A2 (en) 2015-06-12 2018-08-14 Bristol Myers Squibb Co cancer treatment through combined blockade of pd-1 and cxcr4 signaling pathways
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
US10379661B2 (en) 2015-09-25 2019-08-13 Samsung Electronics Co., Ltd. Coordinate measuring apparatus and coordinate measuring system having the same
CN109069486A (en) 2015-12-14 2018-12-21 X4 制药有限公司 The method for the treatment of cancer
ES2907489T3 (en) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Cancer treatment methods
CN108883091A (en) 2015-12-22 2018-11-23 X4 制药有限公司 Method for treating immunologic deficiency disease
JP2019502741A (en) 2016-01-22 2019-01-31 エックス4 ファーマシューティカルズ, インコーポレイテッド Methods for treating cancer
JP2019510785A (en) 2016-04-08 2019-04-18 エックス4 ファーマシューティカルズ, インコーポレイテッド How to treat cancer
US11353459B2 (en) 2016-04-14 2022-06-07 Creatv Microtech, Inc. Methods of using PD-L1 expression in treatment decisions for cancer therapy
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US20200138804A1 (en) 2017-06-21 2020-05-07 X4 Pharmaceuticals, Inc. Methods for treating cancer
US20210349099A1 (en) 2017-11-07 2021-11-11 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
JP2021506838A (en) 2017-12-19 2021-02-22 エックス4 ファーマシューティカルズ, インコーポレイテッド Acyclic CXCR4 Inhibitors and Their Use
CA3095331A1 (en) 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Also Published As

Publication number Publication date
US20240058322A1 (en) 2024-02-22
MX2021002180A (en) 2021-09-14
EA202190377A1 (en) 2021-07-22
US20220008410A1 (en) 2022-01-13
EA202190377A9 (en) 2021-08-09
CN112839649A (en) 2021-05-25
IL281082A (en) 2021-04-29
US11045461B2 (en) 2021-06-29
WO2020047410A1 (en) 2020-03-05
KR20210095118A (en) 2021-07-30
EP3843720A4 (en) 2022-07-27
CA3110735A1 (en) 2020-03-05
JP2021535146A (en) 2021-12-16
US10548889B1 (en) 2020-02-04
US20200253953A1 (en) 2020-08-13
AU2019328530A1 (en) 2021-04-01
EP3843720A1 (en) 2021-07-07
US11672793B2 (en) 2023-06-13
BR112021003467A2 (en) 2021-05-18

Similar Documents

Publication Publication Date Title
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
GB2582482B (en) CASZ compositions and methods of use
IL277889A (en) Oligonucleotide compositions and methods of use thereof
IL291933A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
SG11202111386UA (en) Oligonucleotide compositions and methods of use thereof
GB2582100B (en) CAS12C Compositions and methods of use
IL279475A (en) Ectonucleotidase inhibitors and methods of use thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL287973A (en) Acss2 inhibitors and methods of use thereof
SG11202106585UA (en) Polishing compositions and methods of using same
GB202105087D0 (en) Microbial compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
SG11202106584QA (en) Polishing compositions and methods of using same
EP3691646A4 (en) Inhalable composition of clofazimine and methods of use
IL285247A (en) Enhanced nitrate compositions and methods of use
GB202319843D0 (en) CAS13-based compositions and methods of use thereof
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL282533A (en) Oligosaccharide compositions and methods of use thereof
IL287797A (en) Oligosaccharide compositions and methods of use
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use